Drosophila melanogaster as a rapid in vivo assay system for preclinical anti-seizure medication testing.

ABSTRACT: Epilepsy represents a significant medical challenge, with a third of patients failing to achieve seizure freedom despite the use of multiple different anti-seizure medications (ASM). Drug resistance is common in genetically caused epilepsies. Patients are faced with repeated, long-lasting, and frequently frustrating drug testing, necessitating targeted therapies and drug repurposing. While in silico tools offer some insight, novel and often genetic epilepsies require preclinical models, which are expensive and time-consuming. Here, we propose Drosophila melanogaster as a rapid in vivo model for preclinical ASM efficacy testing using the sodium channel-associated epilepsies, Dravet syndrome (DS), and generalized epilepsy with febrile seizures plus (GEFS+) as model disorders. We utilize vine

SUBMITTER: Tofflinger EV 

PROVIDER: S-EPMC12362156 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature